Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company striving to improve the health and lives of patients.
Upsher‑Smith is the commercial arm of the Bora Group, focused on developing, marketing, and distributing pharmaceutical products that make a real difference for patients We formulate and manufacture generics and brands for a wide array of customers, backed by our attentive level of service, our strong industry relationships, and our dedication to uninterrupted supply.
04/06/2026
Upsher-Smith has launched Ciprofloxacin [0.3%] and Dexamethasone [0.1%] Otic Suspension.
Learn more about our first prescription ear drop suspension and its availability by clicking below:
Read this post on the Upsher-Smith website.
03/30/2026
Honoring the physicians whose dedication drives progress in healthcare.
Your leadership and expertise make a profound impact on patients and communities. Today, we say thank you.
03/09/2026
It’s National Patient Safety Awareness Week — a moment to spotlight the care and vigilance patients deserve. At Upsher-Smith, safety drives every decision we make.
Putting patients first, today and every day.
02/28/2026
At Upsher-Smith, we are dedicated to driving awareness and offering treatment options for patients with rare diseases. Our specialized programs support patients with infantile spasms (IS), Duchenne muscular dystrophy (DMD), and other rare conditions, helping to support patients and their families.
02/24/2026
Did you know that Upsher‑Smith offers a number of heart‑related generics, including therapies used to help manage blood pressure, cholesterol, heart‑rhythm conditions, and electrolyte support?
Caregivers play an essential role in the health of families and communities.
Today, on National Caregivers Day, Upsher-Smith recognizes your unwavering commitment and the impact you make every day. We’re proud to contribute to your efforts by delivering medicines that help support patients.
02/09/2026
On this International Epilepsy Day, Upsher-Smith joins the global community in supporting awareness, understanding, and care for those living with epilepsy.
01/12/2026
Happy National Pharmacist Day! Today we celebrate pharmacists for their expertise, compassion, and dedication to improving patient health. At Upsher-Smith, we are grateful for the vital role pharmacists play in supporting communities and advancing care.
Image credit bzzrincantation
12/19/2025
Wonderful news, and a pivotal moment in the fight against Duchenne muscular dystrophy.
🎉 Today, we’re celebrating an exciting milestone for the community: Duchenne has been added to the Recommended Uniform Screening Panel (RUSP)!
By reducing the diagnostic delays that have affected Duchenne families for generations, early identification through can:
- Allow families to connect with care and neuromuscular experts sooner
- Access approved therapies and supportive interventions earlier
- Improve long-term health outcomes
FACT: Every 12 minutes, a child is diagnosed with infantile spasms worldwide, with onset typically between 3 and 8 months. These seizures are rare but serious, and without prompt diagnosis and treatment, they can lead to developmental delays and brain damage.
This December (Dec 1–7), during Infantile Spasms Awareness Week, take a moment to learn the signs. Because when it comes to a baby’s brain, every second matters.
Upsher-Smith is proud to sponsor ISAW and is committed to supporting families affected by IS.
Learn more about the signs and symptoms at infantilespasms.org.
12/03/2025
Upsher-Smith is proud to announce the launch of KYMBEE™ (deflazacort) Tablets.
KYMBEE™ is the only deflazacort backed by Upsher-Smith’s Promise of Support® Program designed to assist families throughout their treatment journey.
Be the first to know and let us send you an email when Upsher-Smith posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, we’ve formulated and manufactured specialty generics and other products, either independently or with partners, for a wide array of customers, backed by our attentive level of service, our strong industry relationships, and our dedication to uninterrupted supply.
As we celebrate our 100th year in business, we enter a new ambitious era that has been accelerated by our 2017 acquisition by Sawai Pharmaceutical Co., Ltd. With our new owner, we look to leverage each other for growth worldwide and embark on an exciting new chapter. Together, we seek to deliver the best value for our stakeholders, and most importantly, do more good for the patients we serve.